Fused bicyclic compound

A fused bicyclic compound of the following formula [I-B]:

• wherein
• the ring A is optionally substituted with one or two substituents(s) selected from a halogen atom and a C1-8 alkyl group,
• R12 is an alkylsulfonylamino group or an alkylaminosulfonyl group,
• R22 and R32 are (a) the same or different and each is a hydrogen atom or an alkyl group, (b) combined with each other at its terminal together with the adjacent carbon atom to form a cycloalkyl group, or (c) combined with each other to form an oxo group,
• R41 is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom, (d) an alkyl group, (e) an alkenyl group, (f) a cycloalkyl group (g) an alkanoyl group, (h) a carbamoyl group or (i) a cycloalkenyl group,
• Ar2 is a (a) 6- to 10-membered monocyclic or bicyclic aryl group, or (b) 5- to 10-membered monocyclic or bicyclic heteroaryl group optionally containing one or more heteroatom(s) selected from a sulfur atom, an oxygen atom, and a nitrogen atom, said aryl or heteroaryl group being optionally substituted with the same or different one or two substituent(s) selected from a halogen atom, a cyano group, a C1-8 alkyl group, a trihalogeno-C1-8-alkyl group, and a C1-8 alkoxy group,
• a dotted line means presence or absence of a double bond,
• or a pharmaceutically acceptable salt thereof.

A compound of the general [I-B-a] below:

• wherein
• R12 is an alkylsulfonylamino group or an alkylaminosulfonyl group,
• RB, RB2 and RB3 are the same or different and each is a group selected from a hydrogen atom, a halogen atom and an alkyl group,
• R24 and R34 are (a) the same or different and each is a hydrogen atom or an alkyl group, (b) combined each other at its terminal together with the adjacent carbon atom to form a cycloalkyl group, or (c) combined each other to form an oxo group,
• R41 is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom, (d) an alkyl group, (e) an alkenyl group, (f) a cycloalkyl group (g) an alkanoyl group, (h) a carbamoyl group or (i) a cycloalkenyl group,
• Ar21 is a 6-membered aromatic cyclic group optionally substituted with one or two group(s) selected from a halogen atom, an alkyl group, and a trihalogenoalkyl group, wherein said cyclic group may contain one or two nitrogen atom(s) as a heteroatom, and
• a dotted line means presence or absence of a double bond,
• or a pharmaceutically acceptable salt thereof.

A compound selected form a group consisting of:

• N-[4-(4-fluorophenyl)-2,2,3-trimethyl-2H-chromen-7-yl]methanesulfonamide;
• N-[3-cyano-4-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-7-yl]methanesulfonamide;
• N-[3-fluoro-4-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-7-yl]methanesulfonamide;
• N-[4-(4-fluorophenyl)-2,2-dimethyl-3,4-dihydro-2H-chromen-7-yl]methanesulfonamide;
• N-[4-(4-chloro-2-methylphenyl)-2,2-dimethyl-2H-chromen-7-yl]methanesulfonamide;
• N-[3-cyano-4-(4-fluorophenyl)-2,2-diethyl-2H-chromen-7-yl]methanesulfonamide;
• N-[3-cyano-2,2-dimethyl-4-phenyl-2H-chromen-7-yl]methanesulfonamide;
• N-[4-(4-chlorophenyl)-3-cyano-2,2-dimethyl-2H-chromen-7-yl]methanesulfonamide;
• N-[4-(4-chloro-3-methylphenyl)-3-cyano-2,2-dimethyl-2H-chromen-7-yl]-methanesulfonamide;
• N-[4-(4-chloro-3-fluorophenyl)-3-cyano-2,2-dimethyl-2H-chromen-7-yl]-methanesulfonamide;
• N-[4-(4-fluorophenyl)-2,2,5-trimethyl-2H-chromen-7-yl]methanesulfonamide;
• and
• N-[3-cyano-4-(4-fluorophenyl)-2,2,5-trimethyl-2H-chromen-7-yl]methanesulfonamide,
• or a pharmaceutically acceptable salt thereof.

A compound of the general formula [ii] below:

• wherein
• Xa is ═C(CN)—,
• RZ is a hydrogen atom or a halogen atom,
• R25 and R35 are an alkyl group, and
• Ar3 is a phenyl group optionally substituted with one or two group(s) selected from a halogen atom and a trihalogenoalkyl group,
• or a pharmaceutically acceptable salt thereof.